At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 34 enrolled
Drug / intervention
Aspirindrug
Likely dose
Aspirin 81mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacogenomics of Antiplatelet Response
In Brief
A Phase 4 clinical trial evaluating Aspirin for Atherosclerosis. Completed, enrolled 34 participants across 1 site.
Detailed Summary
This clinical trial will examine with effect of 2-week aspirin therapy on platelet gene expression in persons at high-risk of developing heart attacks due to family history of early-onset coronary artery disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJun 2014
First PostedSep 2014
Primary CompletionApr 2015
Study CompletionMay 2015
TodayJul 2026
First PostedSep 9, 2014
Enrollment StartJun 1, 2014
Primary CompletionApr 1, 2015
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 11.8 years ago
Interventions
Aspirindrug
2-week aspirin therapy (81mg/day)